MIRM Stock Analysis: Mirum Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.146m USD | 12M Return: 16.5% | US6047491013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.3M
Qual. Beats: 0
Rev. Trend: 98.7%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mirum Pharmaceuticals is a Foster City, California-based biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its lead commercial product, LIVMARLI (maralixibat), is an oral ileal bile acid transporter (IBAT) inhibitor approved for cholestatic pruritus in patients with Alagille syndrome in the U.S. and internationally. The company also markets Cholbam for bile acid synthesis disorders and Chenodal for radiolucent gallstones, with Chenodal additionally under study for cerebrotendinous xanthomatosis.
Mirums pipeline includes Volixibat (Phase 2b for cholestatic liver diseases), Brelovitug (Phase 2 for chronic hepatitis delta virus infection), and MRM-3379 (Phase 2 for Fragile X syndrome). The company supports its portfolio through a network of collaboration, licensing, and asset purchase agreements with partners including Pfizer, Sanofi, Novartis, Shire, and Travere Therapeutics. Mirum was incorporated in 2018 and listed on NASDAQ under the ticker MIRM following its 2019 IPO.
As an orphan disease specialist, Mirum operates within a biotech subsector that benefits from regulatory incentives such as U.S. Orphan Drug Designation, which typically grants seven years of market exclusivity and fee waivers, and its revenue model relies on premium pricing for therapies targeting small patient populations with limited treatment alternatives.
- LIVMARLI sales surge with PFIC label expansion
- Volixibat pivotal trial data drives pipeline valuation
- Cash burn widens amid heavy pipeline R&D investment
| Net Income: -860.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.42 > 0.02 and ΔFCF/TA -143.6 > 1.0 |
| NWC/Revenue: 66.91% < 20% (prev 71.91%; Δ -5.00% < -1%) |
| CFO/TA -0.44 > 3% & CFO -456.0m > Net Income -860.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.4m) vs 12m ago 27.44% < -2% |
| Gross Margin: 81.70% > 18% (prev 79.02%; Δ 2.68% > 0.5%) |
| Asset Turnover: 69.81% > 50% (prev 59.13%; Δ 10.68% > 0%) |
| Interest Coverage Ratio: -59.74 > 6 (EBIT TTM -802.7m / Interest Expense TTM 13.4m) |
| A: 0.40 (Total Current Assets 636.3m - Total Current Liabilities 222.8m) / Total Assets 1.04b |
| B: -1.46 (Retained Earnings -1.52b / Total Assets 1.04b) |
| C: -0.91 (EBIT TTM -802.7m / Avg Total Assets 885.4m) |
| D: -0.01 (Book Value of Equity -10.4m / Total Liabilities 1.06b) |
| Altman-Z'' = -8.26 = D |
| DSRI: 0.94 (Receivables 145.4m/106.8m, Revenue 618.1m/429.2m) |
| GMI: 0.97 (GM 79.02% / 81.70%) |
| AQI: 1.04 (AQ_t 0.38 / AQ_t-1 0.36) |
| SGI: 1.44 (Revenue 618.1m / 429.2m) |
| TATA: -0.39 (NI -860.2m - CFO -456.0m) / TA 1.04b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 86.01 with a total of 1,139,676 shares traded. Over the past week, the price has changed by +3.71%, over one month by -12.50%, over three months by -32.65% and over the past year by +16.51%.
Current recommended Stop Loss: 81.30 (which is 5.5% or 1.2 ATR below the current price).
Mirum Pharmaceuticals has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy MIRM.
- StrongBuy: 10
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 145.8 | 69.5% |
P/E Forward = 166.6667
P/S = 8.3258
P/B = 26.591
Revenue TTM = 618.1m USD
EBIT TTM = -802.7m USD
EBITDA TTM = -776.8m USD
Long Term Debt = 750.1m USD (from longTermDebt, last quarter)
Short Term Debt = 2.14m USD (from shortTermDebt, last fiscal year)
Debt = 773.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.9m
Net Debt = 335.1m USD (calculated: Debt 773.4m - CCE 438.3m)
Enterprise Value = 5.48b USD (5.15b + Debt 773.4m - CCE 438.3m)
Interest Coverage Ratio = -59.74 (Ebit TTM -802.7m / Interest Expense TTM 13.4m)
EV/FCF = -3.70x (Enterprise Value 5.48b / FCF TTM -1.48b)
FCF Yield = -26.99% (FCF TTM -1.48b / Enterprise Value 5.48b)
FCF Margin = -239.4% (FCF TTM -1.48b / Revenue TTM 618.1m)
Net Margin = -139.2% (Net Income TTM -860.2m / Revenue TTM 618.1m)
Gross Margin = 81.70% ((Revenue TTM 618.1m - Cost of Revenue TTM 113.1m) / Revenue TTM)
Gross Margin QoQ = 82.78% (prev 81.94%)
Tobins Q-Ratio = 5.25 (Enterprise Value 5.48b / Total Assets 1.04b)
Interest Expense / Debt = 1.74% (Interest Expense 13.4m / Debt 773.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -634.2m (EBIT -802.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.58 (Total Current Assets 636.3m / Total Current Liabilities 246.2m)
Debt / Equity = -74.21 (negative equity) (Debt 773.4m / totalStockholderEquity, last quarter -10.4m)
Debt / EBITDA = -0.43 (negative EBITDA) (Net Debt 335.1m / EBITDA -776.8m)
Debt / FCF = -0.23 (negative FCF - burning cash) (Net Debt 335.1m / FCF TTM -1.48b)
Total Stockholder Equity = 209.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -97.15% (Net Income -860.2m / Total Assets 1.04b)
RoE = -410.2% (Net Income TTM -860.2m / Total Stockholder Equity 209.7m)
RoCE = -83.64% (EBIT -802.7m / Capital Employed (Equity 209.7m + L.T.Debt 750.1m))
RoIC = -79.93% (negative operating profit) (NOPAT -634.2m / Invested Capital 793.4m)
WACC = 8.72% (E(5.15b)/V(5.92b) * Re(9.82%) + D(773.4m)/V(5.92b) * Rd(1.74%) * (1-Tc(0.21)))
Discount Rate = 9.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.43 | Cagr: 14.29%
[DCF] Fair Price = unknown (Cash Flow -1.48b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.10 | # QB: 0
Revenue Correlation: 98.74 | Revenue CAGR: 65.35% | SUE: 1.62 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.42 | Chg30d=+38.05% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-15.14 | Chg30d=-6.32% | Revisions=+0% | GrowthEPS=-3121.3% | GrowthRev=+33.6%
EPS next Year (2027-12-31): EPS=-0.35 | Chg30d=-84.41% | Revisions=-25% | GrowthEPS=+97.7% | GrowthRev=+17.6%
[Analyst] Revisions Ratio: -25% (up=0, down=1)